Complaint alleges Anavex Life Sciences Corp. misled investors between November 26, 2025 and August 28, 2026; investors may seek lead plaintiff role by November 30, 2026
LOS ANGELES, Oct. 26, 2026 /PRNewswire/ -- Glancy Prongay Wolke & Rotter LLP ("Glancy") announced today that the class action lawsuit covers investors who bought Anavex Life Sciences Corp. ("Anavex" or the "Company") (NASDAQ: AVXL) securities between November 26, 2025 and August 28, 2026. The Anavex Life Sciences Corp. case, Kurey v. Anavex Life Sciences Corp. et al., was filed on September 29, 2026 in the U.S. District Court for the Southern District of New York (Case No. 26-cv-08567).
Investors who suffered losses on Anavex Life Sciences Corp. investments can submit their Anavex Life Sciences Corp. loss information here before the November 30, 2026 lead plaintiff deadline.
Key dates in the Anavex Life Sciences Corp. case
- Class period: November 26, 2025 to August 28, 2026
- Complaint filed: September 29, 2026
- Lead plaintiff deadline: November 30, 2026
What happened?
On May 11, 2026, the Company filed with the SEC a notification of late filing which disclosed it had "terminated the employment of Dr. Christopher Missling as the Chief Executive Officer of the Company on April 30, 2026 for, among other things, conduct that the Special Committee believed was inconsistent with Company Policy."
On this news, Anavex stock fell $0.18 per share, or 5.55%, to close at $3.06 on May 12, 2026, thereby injuring investors.
Then, on August 28, 2026, Anavex filed an Amended 2025 Annual Report with the SEC. The report stated, in part, that as a result of a review by the Special Committee, management, in consultation with the Audit Committee of the Board, "concluded that there was a material weakness in internal control over financial reporting that existed at September 30, 2025" and that "the Company's disclosure controls and procedures were not effective."
On this news, Anavex stock fell $0.19 per share, or 6.35%, to close at $2.80 on August 31, 2026, thereby injuring investors further.
What is the Anavex Life Sciences Corp. lawsuit about?
The Anavex Life Sciences Corp. securities lawsuit alleges that, between November 26, 2025 and August 28, 2026, defendants made materially false and/or misleading statements and failed to disclose material adverse facts about Anavex Life Sciences Corp.'s business, operations, and prospects. Specifically, the complaint alleges defendants failed to disclose that: (1) Anavex lacked adequate internal controls; (2) Anavex understated its potential regulatory challenges as a result of misconduct by former CEO Christopher Missling; and (3) as a result, defendants' positive statements about Anavex Life Sciences Corp.'s business, operations, and prospects were materially misleading and/or lacked a reasonable basis.
"The complaint against Anavex Life Sciences Corp. alleges, among other things, that the Company failed to disclose that Anavex lacked adequate internal controls. For investors who purchased during the class period, the November 30, 2026 lead plaintiff deadline is the first significant deadline to keep in mind," said Charles H. Linehan, Partner at Glancy Prongay Wolke & Rotter LLP.
What's the next step?
Glancy Prongay Wolke & Rotter LLP is a leading national shareholder rights law firm, ready to assist Anavex Life Sciences Corp. investors in potentially pursuing claims to recover their losses.
If you wish to serve as lead plaintiff in the Anavex Life Sciences Corp. class action, you must move the Court no later than November 30, 2026. To learn more about your rights, visit the Anavex Life Sciences Corp. case page, email shareholders@glancylaw.com, or call 310-201-9150 (toll-free: 888-773-9224).
You may retain counsel of your choice. If you bought Anavex Life Sciences Corp. securities during the class period, you may take no action and remain an absent class member. No class has been certified yet in the Anavex Life Sciences Corp. case.
Frequently Asked Questions
Who is eligible? Investors who purchased or otherwise acquired Anavex Life Sciences Corp. securities between November 26, 2025 and August 28, 2026 and suffered losses may be members of the proposed class in the Anavex Life Sciences Corp. shareholder lawsuit. Any class member may ask the court to appoint them lead plaintiff by November 30, 2026.
What is a lead plaintiff? In the Anavex Life Sciences Corp. class action, the lead plaintiff is the investor, or group of investors, that the court appoints to represent all class members and oversee the case. Under the Private Securities Litigation Reform Act, courts generally presume the movant with the largest financial interest is the most adequate lead plaintiff.
Do I have to be lead plaintiff to recover? No. A Anavex Life Sciences Corp. investor's ability to share in any future recovery does not depend on serving as lead plaintiff. Anavex Life Sciences Corp. investors may take no action and remain absent class members.
What is the deadline? Motions to serve as lead plaintiff in the Anavex Life Sciences Corp. class action must be filed by November 30, 2026.
Does it cost anything to contact Glancy or participate in this action? Glancy represents Anavex Life Sciences Corp. investors on a contingency fee basis, so investors pay no attorneys' fees out of pocket. Any attorneys' fees and litigation expenses are paid only from a recovery, if one is obtained, and are subject to court approval.
Can I choose my own lawyer? Yes. Anavex Life Sciences Corp. investors may retain counsel of their choice.
Why work with Glancy on the Anavex Life Sciences Corp. lawsuit? Glancy Prongay Wolke & Rotter LLP is a premier law firm with decades of experience representing investors and consumers in securities litigation and other complex class action litigation. Contact Glancy about the Anavex Life Sciences Corp. lawsuit. Prior results do not guarantee a similar outcome.
About Glancy Prongay Wolke & Rotter LLP
Glancy was named one of Law360's Securities Groups of the Year and ranked second in total investor recoveries by ISS Securities Class Action Services in 2025.
Glancy's successes have been widely covered by leading news and industry publications, including The Wall Street Journal, The Financial Times, Bloomberg Businessweek, Reuters, the Associated Press, Barron's, Investor's Business Daily, Forbes, and Money.
Prior results do not guarantee a similar outcome.
Related links
- Anavex Life Sciences Corp. case page, Glancy Prongay Wolke & Rotter LLP
- Complaint: Kurey v. Anavex Life Sciences Corp. et al., U.S. District Court for the Southern District of New York
- Form 10-K/A
- Anavex Life Sciences Corp. SEC filings index, EDGAR
- Glancy Prongay Wolke & Rotter LLP
Contact
Charles H. Linehan
Glancy Prongay Wolke & Rotter LLP
1925 Century Park East, Suite 2100
Los Angeles, CA 90067
Email: shareholders@glancylaw.com
Telephone: 310-201-9150 | Toll-free: 888-773-9224
www.glancylaw.com
Follow Glancy on LinkedIn, X, or Facebook.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.
View original content to download multimedia:https://www.prnewswire.com/news-releases/whats-next-for-anavex-life-sciences-corp-shareholders-after-6-35-stock-drop-glancy-prongay-wolke--rotter-llp-explains-securities-fraud-class-action-lead-plaintiff-deadline-302918427.html
SOURCE Glancy Prongay Wolke & Rotter LLP
